A new risk score for patients after first recurrence of stage 4 neuroblastoma aged ≥18 months at first diagnosis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A new risk score for patients after first recurrence of stage 4 neuroblastoma aged ≥18 months at first diagnosis

Published:2019-10-20 Issue:17 Volume:8 Page:7236-7243
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Kreitz Kiana¹,Ernst Angela²,Schmidt René¹,Simon Thorsten³,Fischer Matthias³,Volland Ruth³,Hero Barbara³,Berthold Frank³^ORCID

Affiliation:

1. Institute of Medical Statistics and Clinical Research University of Muenster Muenster Germany

2. Institute of Medical Statistics and Computational Biology University of Cologne Cologne Germany

3. Department of Pediatric Oncology and Hematology University of Cologne Cologne Germany

Funder

Deutsche Krebshilfe

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.2562

Reference14 articles.

1. Historical time to disease progression and progression‐free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early‐phase trials

2. Factors associated with recurrence and survival length following relapse in patients with neuroblastoma

3. Outcome of children with relapsed or refractory neuroblastoma: A meta-analysis of ITCC/SIOPEN European phase II clinical trials

4. Clinical and Biologic Features Predictive of Survival After Relapse of Neuroblastoma: A Report From the International Neuroblastoma Risk Group Project

5. Outcome of children with neuroblastoma after progression or relapse. A retrospective study of the Italian neuroblastoma registry

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical prediction models in children that use repeated measurements with time-varying covariates: a scoping review;Academic Pediatrics;2024-07

2. Targeting refractory/recurrent neuroblastoma and osteosarcoma with anti-CD3×anti-GD2 bispecific antibody armed T cells;Journal for ImmunoTherapy of Cancer;2024-03

3. Targeting GD2-positive Refractory/Resistant Neuroblastoma and Osteosarcoma with Anti- CD3 x Anti-GD2 Bispecific Antibody Armed T cells;2023-11-09

4. A novel clinical tool and risk stratification system for predicting the event-free survival of neuroblastoma patients: A TARGET-based study;Medicine;2023-09-22

5. A novel clinical tool and risk stratification system for predicting the event-free survival of neuroblastoma patients: A TARGET-based study;2022-12-15

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3